Metraipolis › archive › dc_5656bda1296a
Combining Adaptive Seamless Phase II/III Designs and Group Sequential Analysis for Time-to-Event Endpoints in Oncology Trials — arXiv:2610.38301
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2610.38301
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-01T02:31:06.873Z
- SHA-256 of the archived text
d80791a4d72d831079d1fcf16b4b7a930f7a82f41f68f19a68c681404ae8ab50- Stable URL of this page
https://metraipolis.com/documento/dc_5656bda1296a
How to cite
Combining Adaptive Seamless Phase II/III Designs and Group Sequential Analysis for Time-to-Event Endpoints in Oncology Trials — arXiv:2610.38301 — arXiv (en), https://arxiv.org/abs/2610.38301 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_5656bda1296a (Metraipolis archive dc_5656bda1296a, sha256 d80791a4d72d831079d1fcf16b4b7a930f7a82f41f68f19a68c681404ae8ab50)
BibTeX
@misc{dc5656bda1296a,
title = {Combining Adaptive Seamless Phase II/III Designs and Group Sequential Analysis for Time-to-Event Endpoints in Oncology Trials — arXiv:2610.38301},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2610.38301},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_5656bda1296a; sha256 d80791a4d72d831079d1fcf16b4b7a930f7a82f41f68f19a68c681404ae8ab50},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2610.38301. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Seamless Phase II/III designs are a natural vehicle for the randomized dose optimization called for by the US Food and Drug Administration's Project Optimus initiative. Their extension to group sequential repeated testing of a time-to-event endpoint after end-of-Phase-II dose selection, however, remains largely unestablished. Existing proposals index the boundaries for the post-selection looks by the overall information fraction of the primary endpoint---the correct index for the log-rank statistics of an unadapted trial, but not for the combination statistics these designs actually test---and support family-wise error rate (FWER) control by simulation. We instead work from the joint distribution of the combination statistics themselves, calibrating group sequential boundaries separately for each hypothesis in the closure and applying closed testing at every look; a general lemma establishes that this controls the FWER in the strong sense, for any number of hypotheses and analysis times. Specifically, under patient-wise separation and an inverse-normal combination test, the interim and final statistics for an individual hypothesis are bivariate normal, with a correlation determined by how the events at each look divide between the pre- and post-selection cohorts rather than by the overall information fraction, so that their boundaries follow from standard group sequential software; the corresponding statistics for the intersection hypothesis, formed from a Hochberg-adjusted Stage-1 $p$-value, are not multivariate normal, and we obtain their boundaries by a dedicated numerical integration. Head-to-head against a recently proposed incremental-Dunnett procedure, the two were near-identical when the design projections were correct, but ours was more robust when the combination weights were based on a misprojected division of the Stage~1 events either side of the interim. Tema degli esploratori: statistica e scienza dei dati (elenco arXiv stat.ME, nuovi lavori del giorno). Categorie arXiv: Methodology (stat.ME) ; Applications (stat.AP). Pagina del lavoro: https://arxiv.org/abs/2610.38301 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-11-01T02:13:43.970Z dalla pagina https://arxiv.org/list/stat.ME/new (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).